Literature DB >> 11044476

Celiac disease diagnosis in misdiagnosed children.

A Picarelli1, L Sabbatella, M Di Tola, F Gabrielli, R Greco, T Di Cello, A Mastracchio, M C Anania.   

Abstract

Antiendomysial antibodies (EMA) are today considered the most sensitive and specific serological marker of celiac disease (CD). The aim of the present study was to assess the occurrence of EMA of IgG isotype in EMA IgA negative children with clinical suspicion of malabsorption and their relationship with CD. Serum EMA IgG1 determination was performed on 30 EMA IgA negative children with clinical suspicion of CD. Total serum IgA levels were further investigated. Sixty children with gastroenterological diseases other than CD were used as control disease patients and 63 healthy children were evaluated as the control group. Eighteen out of 30 children in the study showed EMA IgG1 positivity in sera and a villous height/crypt depth ratio <3:1 as index of intestinal atrophy. It is noticeable that a selective IgA deficiency was present in only 9 of 18 EMA IgG1 positive children. In addition, clinical symptoms, EMA IgG1, and mucosal atrophy disappeared after 8-10 mo on a gluten-free diet. Neither EMA IgA nor EMA IgG1 were detected in the children in the control groups. The other 12 children in study group showed no histologic abnormalities and were EMA IgG1 negative. In this study, we reveal a group of EMA IgG1 CD children without IgA deficiency. The diagnosis was based on the presence of gluten-dependent typical serological and histologic features of CD. Our data suggest that EMA IgG1 determination could be a new tool in the diagnostic workup of CD, useful in avoiding possible misdiagnosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044476     DOI: 10.1203/00006450-200011000-00006

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

1.  Increased risk of surgery in undiagnosed celiac disease.

Authors:  C Ciacci; R Cavallaro; R Romano; D S Galletta; F Labanca; M Marino; M Donisi; G Mazzacca
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

Review 2.  Do you still need a biopsy to diagnose celiac disease?

Authors:  S Guandalini; P Gupta
Journal:  Curr Gastroenterol Rep       Date:  2001-10

3.  The high frequency of coeliac disease and other autoimmune diseases in subjects affected by Type I (insulin-dependent) diabetes mellitus and in their first-degree relatives.

Authors:  L Sabbatella; M Di Tola; A Picarelli
Journal:  Diabetologia       Date:  2002-05       Impact factor: 10.122

4.  Anti-endomysial antibody of IgG1 isotype detection strongly increases the prevalence of coeliac disease in patients affected by type I diabetes mellitus.

Authors:  A Picarelli; L Sabbatella; M Di Tola; S Vetrano; C Casale; M C Anania; B Porowska; M Vergari; R Schiaffini; P Gargiulo
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

5.  The role of antitissue transglutaminase assay for the diagnosis and monitoring of coeliac disease: a French-Italian multicentre study.

Authors:  E Tonutti; D Visentini; N Bizzaro; M Caradonna; L Cerni; D Villalta; R Tozzoli
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

6.  Elevation of IgG antibodies against tissue transglutaminase as a diagnostic tool for coeliac disease in selective IgA deficiency.

Authors:  I R Korponay-Szabó; I Dahlbom; K Laurila; S Koskinen; N Woolley; J Partanen; J B Kovács; M Mäki; T Hansson
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

7.  Cost-effectiveness analysis of strategies for diagnosing celiac disease.

Authors:  Spencer D Dorn; David B Matchar
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

8.  Role of anti-tissue transglutaminase IgA+IgG antibodies in detection of potential celiac disease in patients with type 1 diabetes.

Authors:  Navchetan Kaur; Ranjana W Minz; Sanjay K Bhadada; Biman Saikia; Devi Dayal; Shashi Anand; Neha Joshi; Jagdeep Singh; Babu R Thapa; Rakesh K Kochhar; Kim Vaiphei
Journal:  Indian J Med Res       Date:  2019-01       Impact factor: 2.375

9.  Mass screening for coeliac disease using antihuman transglutaminase antibody assay.

Authors:  A Tommasini; T Not; V Kiren; V Baldas; D Santon; C Trevisiol; I Berti; E Neri; T Gerarduzzi; I Bruno; A Lenhardt; E Zamuner; A Spanò; S Crovella; S Martellossi; G Torre; D Sblattero; R Marzari; A Bradbury; G Tamburlini; A Ventura
Journal:  Arch Dis Child       Date:  2004-06       Impact factor: 3.791

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.